gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2024-34-1-70-75gastro-j-845Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГИИ, ГЕПАТОЛОГИИNATIONAL COLLEGE OF GASTROENTEROLOGY, HEPATOLOGYСовременные возможности применения акотиамида в лечении функциональной диспепсииModern Possibilities of Using Acotiamide in the Treatment of Functional Dyspepsiahttps://orcid.org/0000-0002-1395-9566ШептулинА. А.SheptulinA. A.

Шептулин Аркадий Александрович — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского 

119435, г. Москва, ул. Погодинская, 1, стр. 1

Arkadiy    A.    Sheptulin    —    Dr.    Sci.    (Med.),    Professor at the Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology, N.V. Sklifosovsky Institute of Clinical Medicine

119435, Moscow, Pogodinskaya str., 1, build. 1

arkalshep@gmail.comhttps://orcid.org/0000-0003-4017-4702РаботяговаЮ. С.RabotyagovaYu. S.

Работягова Юлия Сергеевна — кандидат медицинских наук, ассистент кафедры терапии, гастроэнтерологии, кардиологии и общей врачебной практики (семейной медицины)

295006, г. Симферополь, бульв. Ленина, 5/7

Yulia S. Rabotyagova — Cand. Sci. (Med.), Teaching Assistant at the Department of Therapy, Gastroenterology, Cardiology and General Medical Practice (Family Medicine)

295006, Simferopol, Lenina blvrd, 5/7

yliyarabotyagova@gmail.comФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationМедицинский институт им. С.И. Георгиевского ФГАОУ ВО «Крымский федеральный университет им. В.И. Вернадского»Russian FederationMedical Institute named after G.I. Georgievsky of V.I. Vernadsky Crimean Federal UniversityRussian Federation2024190320243417075Copyright © Шептулин А.А., Работягова Ю.С., 20242024Шептулин А.А., Работягова Ю.С.Sheptulin A.A., Rabotyagova Y.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/845Цель обзора

Цель обзора. Оценить эффективность и безопасность применения нового прокинетического препарата акотиамида при лечении функциональной диспепсии.

Основные положения

Основные положения. Акотиамид является антагонистом ингибиторных мускариновых рецепторов 1-го и 2-го типа и обратимым ингибитором активности ацетилхолинэстеразы. У пациентов с функциональной диспепсией акотиамид нормализует аккомодацию фундального отдела желудка и ускоряет замедленное опорожнение желудка. Проведенные исследования подтвердили более высокую эффективность акотиамида по сравнению с плацебо в уменьшении выраженности таких симптомов функциональной диспепсии, как чувство переполнения и вздутия в подложечной области после еды, раннее насыщение. Преимуществом акотиамида по сравнению с другими прокинетиками (в частности, метоклопрамидом и домперидоном) является высокая безопасность применения и отсутствие влияния на продолжительность интервала Q-T.

Заключение

Заключение. Высокая эффективность и безопасность применения делает целесообразным использование акотиамида в лечении больных с функциональной диспепсией.

Aim

Aim: to evaluate the efficacy and safety of the new prokinetic drug acotiamide in the treatment of functional dyspepsia.

Key findings

Key findings. Acotiamide is an antagonist of inhibitory muscarinic receptors of type 1 and 2 and a reversible inhibitor of acetylcholinesterase activity. In patients with functional dyspepsia acotiamide normalizes the accommodation of the fundal part of the stomach and accelerates delayed gastric emptying. The conducted studies have confirmed the higher efficacy of acotiamide compared to placebo in reducing the severity of such symptoms of functional dyspepsia as a feeling of epigastric postprandial fullness and bloating, early satiation. The advantage of acotiamide in comparison to other prokinetics (in particular, metoclopramide and domperidone) is the high safety of use and the absence of influence on the duration of the Q-T interval.

Conclusion

Conclusion. The high efficacy and safety of the application makes it advisable to use acotiamide in the treatment of patients with functional dyspepsia.

функциональная диспепсиялечениеакотиамидfunctional dyspepsiaprokineticsacotiamideReferencesStanghellini V., Chan F.K.L., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–92. DOI: 10.1053/j.gastro.2016.02.011Stanghellini V., Chan F.K.L., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–92. DOI: 10.1053/j.gastro.2016.02.011Aziz A., Palsson O.S., Törnblom H., Sperber A.D., Whitehead W.E., Simrén M. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: A cross-sectional population-based study. Lancet Gastroenterol Hepatol. 2018;3(4):252–62. DOI: 10.1016/S2468-1253(18)30003-7Aziz A., Palsson O.S., Törnblom H., Sperber A.D., Whitehead W.E., Simrén M. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: A cross-sectional population-based study. Lancet Gastroenterol Hepatol. 2018;3(4):252–62. DOI: 10.1016/S2468-1253(18)30003-7Ивашкин В.Т., Шептулин А.А., Киприанис В.А. Функциональная диспепсия. М.: МЕДпресс-информ, 2017.Ivashkin V.T., Sheptulin A.A., Kiprianis B.A. Functional dyspepsia. Moscow: MEDpress-inform, 2017. (In Russ.).D oi Y., Murasaki O., Kaibara M., Uezono Y., Hayashi H., Yano K., et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol. 2004;505(1–3):31–5. DOI: 10.1016/j.ejphar.2004.10.003D oi Y., Murasaki O., Kaibara M., Uezono Y., Hayashi H., Yano K., et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol. 2004;505(1–3):31–5. DOI: 10.1016/j.ejphar.2004.10.003Matsunaga Y., Tanaka T., Yoshinaga K., Ueki S., Hori Y., Eta R., et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: Comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011;336(3):791–800. DOI: 10.1124/jpet.110.174847Matsunaga Y., Tanaka T., Yoshinaga K., Ueki S., Hori Y., Eta R., et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: Comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011;336(3):791–800. DOI: 10.1124/jpet.110.174847Vandenberghe A., Schol J., Van den Houte K., Masuy I., Carbone F., Tack J. Current and emerging therapeutic options for the management of functional dyspepsia. Expert Opin Pharmacother. 2020;21(3):365–76. DOI: 10.1080/14656566.2019.1707805Vandenberghe A., Schol J., Van den Houte K., Masuy I., Carbone F., Tack J. Current and emerging therapeutic options for the management of functional dyspepsia. Expert Opin Pharmacother. 2020;21(3):365–76. DOI: 10.1080/14656566.2019.1707805Sun Y., Song G., McCallum R.W. Evaluation of acotiamide for the treatment of functional dyspepsia. Expert Opin Drug Metab Toxicol. 2014;10(8):1161–8. DOI: 10.1517/17425255.2014.920320Sun Y., Song G., McCallum R.W. Evaluation of acotiamide for the treatment of functional dyspepsia. Expert Opin Drug Metab Toxicol. 2014;10(8):1161–8. DOI: 10.1517/17425255.2014.920320Kusunoki H., Haruma K., Manabe N., Imamura H., Kamada T., Shiotani A., et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: Randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540–5. DOI: 10.1111/j.1365-2982.2012.01897.xKusunoki H., Haruma K., Manabe N., Imamura H., Kamada T., Shiotani A., et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: Randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540–5. DOI: 10.1111/j.1365-2982.2012.01897.xNakamura K., Tomita T., Tadayuki O., Asano H., Yamasaki T., Okugawa T., et al. A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia. J Gastroenterol. 2017;52(5):602–10. DOI: 10.1007/s00535-016-1260-7Nakamura K., Tomita T., Tadayuki O., Asano H., Yamasaki T., Okugawa T., et al. A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia. J Gastroenterol. 2017;52(5):602–10. DOI: 10.1007/s00535-016-1260-7Kaai M., Inamori M., Matsuura M., Iwata Y., Iida H., Fujita K., et al. Early effects of acotiamide or mosapride intake on gastric emptying: A randomized 3-way crossover study using the 13C breath test. J Clin Biohem Nutr. 2021;68(3):264–7. DOI: 10.3164/jcbn.20-162Kaai M., Inamori M., Matsuura M., Iwata Y., Iida H., Fujita K., et al. Early effects of acotiamide or mosapride intake on gastric emptying: A randomized 3-way crossover study using the 13C breath test. J Clin Biohem Nutr. 2021;68(3):264–7. DOI: 10.3164/jcbn.20-162Zai H., Matsueda K., Kusano M., Urita Y., Saito Y., Kato H. Effect of acotiamide on gastric emptying in healthy adult humans. Eur J Clin Invest. 2014;44(12):1215–21. DOI: 10.1111/eci.12367Zai H., Matsueda K., Kusano M., Urita Y., Saito Y., Kato H. Effect of acotiamide on gastric emptying in healthy adult humans. Eur J Clin Invest. 2014;44(12):1215–21. DOI: 10.1111/eci.12367Matsueda K., Hongo M., Tack J., Saito Y., Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821–8. DOI: 10.1136/gutjnl-2011-301454Matsueda K., Hongo M., Tack J., Saito Y., Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821–8. DOI: 10.1136/gutjnl-2011-301454Shinozaki S., Osawa H., Sakamoto H., Hayashi Y., Kawarai Lefor A., Yamamoto H. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. J Med Invest. 2016;63(3–4):230–5. DOI: 10.2152/jmi.63.230Shinozaki S., Osawa H., Sakamoto H., Hayashi Y., Kawarai Lefor A., Yamamoto H. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. J Med Invest. 2016;63(3–4):230–5. DOI: 10.2152/jmi.63.230Porika S., Veliganda K.C., Muni S.K., Acharya S., Mehta S.C., Sharma A.D. Real-world, non-interventional, observational study to evaluate effectiveness and tolerability of acotiamide hydrochloride hydrate in treatment of functional dyspepsia. Adv Ther. 2018;35(11):1884–93. DOI: 10.1007/s12325-018-0814-xPorika S., Veliganda K.C., Muni S.K., Acharya S., Mehta S.C., Sharma A.D. Real-world, non-interventional, observational study to evaluate effectiveness and tolerability of acotiamide hydrochloride hydrate in treatment of functional dyspepsia. Adv Ther. 2018;35(11):1884–93. DOI: 10.1007/s12325-018-0814-xMatsueda K., Hongo M., Tack J., Aoki H., Saito Y., Kato H. Clinical trial: Dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22(6):618–e173. DOI: 10.1111/j.1365-2982.2009.01449.xMatsueda K., Hongo M., Tack J., Aoki H., Saito Y., Kato H. Clinical trial: Dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22(6):618–e173. DOI: 10.1111/j.1365-2982.2009.01449.xXiao G., Xie X., Fan J., Deng J., Tan S., Zhu Y., et al. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: Systematic review and meta-analysis. ScientificWorldJournal. 2014;2014:541950. DOI: 10.1155/2014/541950Xiao G., Xie X., Fan J., Deng J., Tan S., Zhu Y., et al. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: Systematic review and meta-analysis. ScientificWorldJournal. 2014;2014:541950. DOI: 10.1155/2014/541950Shinozaki S., Osawa H., Sakamoto H., Hayashi Y., Kobayashi Y., Miura Y., et al. Timing and predictors of recurrence of dyspepsia symptoms after cessation of acotiamide therapy for functional dyspepsia: A long-term observational study. Digestion. 2020;101(4):382–90. DOI: 10.1159/000500134Shinozaki S., Osawa H., Sakamoto H., Hayashi Y., Kobayashi Y., Miura Y., et al. Timing and predictors of recurrence of dyspepsia symptoms after cessation of acotiamide therapy for functional dyspepsia: A long-term observational study. Digestion. 2020;101(4):382–90. DOI: 10.1159/000500134Shinozaki S., Osawa H., Sakamoto H., Hayashi Y., Miura Y., Kawarai Lefor A., et al. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia. J Gastrointestin Liver Dis. 2017;26(4):345–50. DOI: 10.15403/jgld.2014.1121.264.skiShinozaki S., Osawa H., Sakamoto H., Hayashi Y., Miura Y., Kawarai Lefor A., et al. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia. J Gastrointestin Liver Dis. 2017;26(4):345–50. DOI: 10.15403/jgld.2014.1121.264.skiMuta K., Ihara E., Fukaura K., Tsuchida O., Ochiai T., Nakamura K. Effects of acotiamide on the esophageal motility function in patients with esophageal motility disorders: A pilot study. Digestion. 2016;94(1):9–16. DOI: 10.1159/000447010Muta K., Ihara E., Fukaura K., Tsuchida O., Ochiai T., Nakamura K. Effects of acotiamide on the esophageal motility function in patients with esophageal motility disorders: A pilot study. Digestion. 2016;94(1):9–16. DOI: 10.1159/000447010Funaki Y., Ogasavara N., Kawamura Y., Yoshimine T., Tamura Y., Izawa S., et al. Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study. Neurogastroenterol Motil. 2020;32(2):e13749. DOI: 10.1111/nmo.13749Funaki Y., Ogasavara N., Kawamura Y., Yoshimine T., Tamura Y., Izawa S., et al. Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study. Neurogastroenterol Motil. 2020;32(2):e13749. DOI: 10.1111/nmo.13749Yamawaki H., Futagami S., Kawagoe T., Maruki Y., Hashimot S., Nagoya H., et al. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil. 2016;28(7):1037–47. DOI: 10.1111/nmo.12805Yamawaki H., Futagami S., Kawagoe T., Maruki Y., Hashimot S., Nagoya H., et al. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil. 2016;28(7):1037–47. DOI: 10.1111/nmo.12805Mayanagi S., Kishino M., Kitagawa Y., Sunamura M. Efficacy of acotiamide in combination with esomeprazole for functional dyspepsia refractory to proton-pump inhibitor monotherapy. Tohoku J Exp Med. 2014;234(3):237– 40. DOI: 10.1620/tjem.234.237Mayanagi S., Kishino M., Kitagawa Y., Sunamura M. Efficacy of acotiamide in combination with esomeprazole for functional dyspepsia refractory to proton-pump inhibitor monotherapy. Tohoku J Exp Med. 2014;234(3):237– 40. DOI: 10.1620/tjem.234.237Takeuchi T., Takahashi Y., Kawaguchi S., Ota K., Harada S., Kojima Y., et al. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. J Gastroenterol Hepatol. 2018;33(3):623–30. DOI: 10.1111/jgh.13970Takeuchi T., Takahashi Y., Kawaguchi S., Ota K., Harada S., Kojima Y., et al. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. J Gastroenterol Hepatol. 2018;33(3):623–30. DOI: 10.1111/jgh.13970Hojo M., Nagahara A., Asaoka D., Takeda T., Izumi K., Matsumoto K., et al. A randomized, double-blind, pilot study of the effect of famotidine on acotiamide treatment for functional dyspepsia. Digestion. 2017;96(1):5–12. DOI: 10.1159/000477345Hojo M., Nagahara A., Asaoka D., Takeda T., Izumi K., Matsumoto K., et al. A randomized, double-blind, pilot study of the effect of famotidine on acotiamide treatment for functional dyspepsia. Digestion. 2017;96(1):5–12. DOI: 10.1159/000477345Sinha S., Chary S., Thakur P., Talluri L., Reddy M., Mohan J.M., et al. Efficacy and safety of acotiamide versus mosapride in patients with functional dyspepsia associated with meal-induced postprandial distress syndrome: A phase III randomized clinical trial. Cureus. 2021;13(9):e18109. DOI: 10.7759/cureus.18109Sinha S., Chary S., Thakur P., Talluri L., Reddy M., Mohan J.M., et al. Efficacy and safety of acotiamide versus mosapride in patients with functional dyspepsia associated with meal-induced postprandial distress syndrome: A phase III randomized clinical trial. Cureus. 2021;13(9):e18109. DOI: 10.7759/cureus.18109Yang Y.J., Bang C.S., Baik G.H., Park T.Y., Shin S.P., Suk K.T., et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol. 2017;17(1):83. DOI: 10.1186/s12876-017-0639-0Yang Y.J., Bang C.S., Baik G.H., Park T.Y., Shin S.P., Suk K.T., et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol. 2017;17(1):83. DOI: 10.1186/s12876-017-0639-0Giudicessi J.R., Ackerman M.J., Camilleri M. Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. Neurogastroenterol Motil. 2018;30(6):e13302. DOI: 10.1111/nmo.13302Giudicessi J.R., Ackerman M.J., Camilleri M. Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. Neurogastroenterol Motil. 2018;30(6):e13302. DOI: 10.1111/nmo.13302Shrestha D.B., Budhathoki P., Subedi P., Rhadka M., Rarki P., Sedhai Y.R., et al. Acotiamide and functional dyspepsia: A systematic review and meta-analysis. Cureus. 2021;13(12):e20532. DOI: 10.7759/cureus.20532Shrestha D.B., Budhathoki P., Subedi P., Rhadka M., Rarki P., Sedhai Y.R., et al. Acotiamide and functional dyspepsia: A systematic review and meta-analysis. Cureus. 2021;13(12):e20532. DOI: 10.7759/cureus.20532Mizukami K., Katsuta M., Okamoto K., Fukuda K., Ogawa R., Kawahara Y., et al. Influence of acotiamide on 13C-urea breath test for Helicobacter pylori diagnosis. J Clin Biochem Nutr. 2020;67(3):332–7. DOI: 10.3164/jcbn.20-17Mizukami K., Katsuta M., Okamoto K., Fukuda K., Ogawa R., Kawahara Y., et al. Influence of acotiamide on 13C-urea breath test for Helicobacter pylori diagnosis. J Clin Biochem Nutr. 2020;67(3):332–7. DOI: 10.3164/jcbn.20-17Miwa H., Nagahara A., Asakawa A., Arai M., Oshima T., Kasugai K., et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. 2022;57(2):47–61. DOI: 10.1007/s00535-021-01843-7Miwa H., Nagahara A., Asakawa A., Arai M., Oshima T., Kasugai K., et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. 2022;57(2):47–61. DOI: 10.1007/s00535-021-01843-7Black C.J., Paine P.A., Agrawal A., Aziz I., Eugenicos M.P., Houghton L.A., et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut. 2022;71(9):1697–723. DOI: 10.1136/gutjnl-2022-327737Black C.J., Paine P.A., Agrawal A., Aziz I., Eugenicos M.P., Houghton L.A., et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut. 2022;71(9):1697–723. DOI: 10.1136/gutjnl-2022-327737Ивашкин В.Т., Маев И.В., Шептулин А.А., Лапина Т.Л., Трухманов А.С., Картавенко И.М. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(1):50–61. DOI: 10.22416/1382-4376-2017-27-1-50-61Ivashkin V.T., Maev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M., et al. Diagnosis and treatment of the functional dyspepsia: Clinical guidelines of the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50–61. (In Russ.). DOI: 10.22416/1382-4376-2017-27-1-50-61

The authors declare that there are no conflicts of interest present.